MR1 and cancer: Exogenous pyridoxal and, to a lesser degree, PLP were shown to activate T cells expressing the MAIT T cell receptor (TCR) A-F7 and the MR1-restricted, cancer-reactive MC.7.G5 TCR,4 suggesting a potential role of these ligands in MR1-mediated immune recognition.